Risk factors
Palisade Bio (PALI) risk factors
Item 1A of every Palisade Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks8 new4 dropped10 reworded
PALI-2108 produced positive Phase 1 results; exploratory Phase 1b FSCD dosing began while chronic safety studies continue.
Filed Mar 20, 2026 - FY2024 10-K risk factors49 risks
Palisade Bio faces substantial going concern doubt with net losses of $14.4 million for 2024 and insufficient capital to complete development. The company relies entirely on its lead asset PALI-2108, currently in a Phase 1 clinical trial in Canada for ulcerative colitis. Operations depend heavily on third-party manufacturers, license agreements like the Giiant agreement, and additional equity financing.
Filed Mar 24, 2025